Shunsuke Kondo

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 158 publications

Diagnostic Test Analysis of Intraoperative Direct Sonication in Detecting Periprosthetic Joint Infection: A Systematic Review and Meta-Analysis.

Diagnostic Test Analysis of Intraoperative Direct Sonication in Detecting Periprosthetic Joint Infection: A Systematic Review and Meta-Analysis.

Journal: Cureus

Published: June 10, 2026

Evidence of Higgs Boson Inclusive Production at High Transverse Momentum Decaying to a Pair of b-Quarks with the ATLAS Detector.

Evidence of Higgs Boson Inclusive Production at High Transverse Momentum Decaying to a Pair of b-Quarks with the ATLAS Detector.

Journal: Physical review letters

Published: March 24, 2026

Combination of Measurements of CP Properties of Higgs Boson Interactions with Vector Bosons Using Proton-Proton Collisions at sqrt[s]=13 TeV with the ATLAS Detector.

Combination of Measurements of CP Properties of Higgs Boson Interactions with Vector Bosons Using Proton-Proton Collisions at sqrt[s]=13 TeV with the ATLAS Detector.

Journal: Physical review letters

Published: March 24, 2026

Impact of travel costs on disparities in precision oncology clinical trials.

Impact of travel costs on disparities in precision oncology clinical trials.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Expanding indications and developmental landscape of HER2-targeted therapies in breast cancer: a pharmacotherapeutic perspective.

Expanding indications and developmental landscape of HER2-targeted therapies in breast cancer: a pharmacotherapeutic perspective.

Journal: Expert opinion on pharmacotherapy

Published: November 17, 2025

PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC.

PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC.

Journal: Journal for immunotherapy of cancer

Published: November 17, 2025

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 18, 2025

Efficacy and safety of peptide radionuclide therapy with 177Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N).

Efficacy and safety of peptide radionuclide therapy with 177Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N).

Journal: Journal of gastroenterology

Published: September 02, 2025

Noninvasive detection of pancreatic ductal adenocarcinoma in high-risk patients using miRNA from urinary extracellular vesicles.

Noninvasive detection of pancreatic ductal adenocarcinoma in high-risk patients using miRNA from urinary extracellular vesicles.

Journal: Frontiers in oncology

Published: August 08, 2025

E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study.

E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study.

Journal: ESMO open

Published: July 09, 2025

Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers.

Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers.

Journal: ESMO open

Published: March 31, 2025

Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.

Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 15, 2025

Showing 1-12 of 158

Last Updated: 09/26/2026